All multicellular animals have an innate immune system: When bacteria, parasites or fungi invade the organism, small protein molecules are released that eliminate the attackers. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered a new molecule that plays an important role in triggering the innate immune response of the fruit fly Drosophila, mice and even humans. Their work has just been published in the journal Nature Immunology.
The cells of the innate immune system recognize hostile invaders with the aid of receptors on their surface: The moment these receptors recognize a foreign structure, they send a message, via a complicated signaling pathway, into the cells interior. The cell then releases immunologically active proteins. The components of this signaling pathway have been conserved surprisingly well through evolution; the various signaling molecules are very similar from fly to man, both in structure and in function.
A group of scientists headed by Dr. Michael Boutros of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), collaborating with colleagues of the Centre National de la Recherche Scientifique (CNRS) in Strasbourg, made use of this fact: Using the Nobel-prize winning method of RNA interference (RNAi), they switched off individual molecules of the signaling pathway in Drosophila and have thus come across a new member: Akirin, meaning "making things clear" in Japanese. When they suppressed Akirin production in the immune cells of the flies, these were significantly more susceptible to bacterial infections. And when they knocked down the protein in all body cells, the fly larvae died in an early stage. Colleagues at Japan's Osaka University investigated the corresponding mouse Akirin: In mice, too, the protein fulfills the same function as in the fruit fly and in man.
"What is called the NF-B signaling pathway plays an important role in inflammations, and inflammations are highly relevant in cancer development," said Michael Boutros. "Therefore, the search is on for small molecules that can inhibit this signaling pathway." First inhibitors acting against other links in the signaling chain are already being tested in clinical trials. "The more links of this chain we know, the more possibilities we have to interfere with it," said Boutros explaining the aim of his work.
|Contact: Stefanie Seltmann|
Helmholtz Association of German Research Centres